Literature DB >> 32741483

Acromegaly: Update on Management and Long-Term Morbidities.

Leandro Kasuki1, Ximene Antunes2, Elisa Baranski Lamback2, Mônica R Gadelha3.   

Abstract

Acromegaly is a systemic disease associated with great morbidity and increased mortality if not adequately treated. In the past decades much improvement has been achieved in its treatment and in the knowledge of its comorbidities. We provide an update of acromegaly management with current recommendations. We also address long-term comorbidities emphasizing the changing face of the disease in more recent series, with a decrease of cardiovascular disease severity and an increased awareness of comorbidities like bone disease, manifested mainly as vertebral fractures and the change in the main cause of death (from cardiovascular disease to cancer in more recent series).
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acromegaly; Comorbidities; Pituitary adenoma; Somatotropinoma; Treatment

Mesh:

Year:  2020        PMID: 32741483     DOI: 10.1016/j.ecl.2020.05.007

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  5 in total

Review 1.  Towards an Earlier Diagnosis of Acromegaly and Gigantism.

Authors:  Jill Sisco; A J van der Lely
Journal:  J Clin Med       Date:  2021-03-26       Impact factor: 4.241

Review 2.  Safety of Pediatric rhGH Therapy: An Overview and the Need for Long-Term Surveillance.

Authors:  Stefano Cianfarani
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

3.  Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience.

Authors:  Sabrina Chiloiro; Antonella Giampietro; Irene Gagliardi; Marta Bondanelli; Miriam Veleno; Maria Rosaria Ambrosio; Maria Chiara Zatelli; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis; Antonio Bianchi
Journal:  Pituitary       Date:  2022-08-03       Impact factor: 3.599

Review 4.  MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands.

Authors:  Daniel G Henriques; Elisa B Lamback; Romulo S Dezonne; Leandro Kasuki; Monica R Gadelha
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

5.  Renal effects of growth hormone in health and in kidney disease.

Authors:  Dieter Haffner; Andrea Grund; Maren Leifheit-Nestler
Journal:  Pediatr Nephrol       Date:  2021-06-18       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.